Politico December 13, 2024
Erin Schumaker and Daniel Payne with Carmen Paun

THE NEXT CURES

Psychedelics could offer relief to doctors who provided frontline care during the pandemic and later became depressed.

That’s according to a small new study published in JAMA Network Open this month.

Inside the study: Of the 30 participants in the double-blind, randomized trial, half received two preparation sessions; one dose of synthetic psilocybin, also known as magic mushrooms; and three follow-up counseling sessions with a trained facilitator. The other half, the control group, received the same sequence of sessions, except a placebo was swapped for the psilocybin.

While both groups saw their depression symptoms improve, participants in the psilocybin group had faster, bigger and more long-lasting drops in their depression scores.

Because the study was small, its...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID, Trends
Science magazine names HIV drug its 'Breakthrough of the Year'
Integrating Equity Into Licensing Agreements For Taxpayer-Funded Technologies
How Technology Could Speed And Support Disaster Response
Food recalls seem increasingly common. Why?
The year that Covid created

Share This Article